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Abstract
Background: The benefit of routine HIV-1 viral load (VL) monitoring of patients on antiretroviral therapy (ART) in resource-
constrained settings is uncertain because of the high costs associated with the test and the limited treatment options. We
designed a cluster randomized controlled trial to compare the use of routine VL testing at ART-initiation and at 3, 6, 12, and
18 months, versus our local standard of care (which uses immunological and clinical criteria to diagnose treatment failure,
with discretionary VL testing when the two do not agree).
Methodology: Dedicated study personnel were integrated into public-sector ART clinics. We collected participant
information in a dedicated research database. Twelve ART clinics in Lusaka, Zambia constituted the units of randomization.
Study clinics were stratified into pairs according to matching criteria (historical mortality rate, size, and duration of
operation) to limit the effect of clustering, and independently randomized to the intervention and control arms. The study
was powered to detect a 36% reduction in mortality at 18 months.
Principal Findings: From December 2006 to May 2008, we completed enrollment of 1973 participants. Measured baseline
characteristics did not differ significantly between the study arms. Enrollment was staggered by clinic pair and truncated at
two matched sites.
Conclusions: A large clinical trial of routing VL monitoring was successfully implemented in a dynamic and rapidly growing
national ART program. Close collaboration with local health authorities and adequate reserve staff were critical to success.
Randomized controlled trials such as this will likely prove valuable in determining long-term outcomes in resource-
constrained settings.
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Introduction
The rapid expansion of access to antiretroviral therapy (ART) in
sub-Saharan Africa has led to dramatic drops in AIDS-related
mortality in a variety of settings, [1,2,3,4,5] but a tremendous
unmet need for HIV care remains. [6] Limited healthcare
infrastructure, personnel, and funding create a tension between
the twin goals of expanding access to ART and optimizing care
for those already receiving treatment. Arguments to minimize
sophisticated laboratory monitoring in favor of treatment program
expansion [7] must be weighed against the potential for improved
outcomes and cost savings associated with better tools for
monitoring treatment. [8]
The measurement of HIV-1 RNA levels (i.e., viral load [VL]) is
recommended to monitor the response to ART in developed
countries. [9,10] The World Health Organization (WHO) does
not recommend routine VL testing in resource-constrained
settings, in part due to the cost and complex infrastructure needed
for reliable results. [11] In these settings, WHO has proposed the
use of clinical and CD4
+ lymphocyte-based criteria to guide
treatment decisions. However, multiple studies have demonstrated
the poor performance of these criteria in sub-Saharan Africa and
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9680the frequent discordance between immunologic and virologic
responses to ART. [12,13,14,15]
Given the lack of third-line ART regimens in much of
sub-Saharan Africa and the high cost, sophisticated laboratory
equipment, and technical training necessary to perform VL
testing, the widespread adoption of this technology must be
informed by solid evidence. To obtain these data, we implemented
a large clinical trial investigating the public health impact of
routine virologic monitoring on patient outcomes in Lusaka,
Zambia. A clinic-level, cluster-randomized design was selected as
most appropriate from a logistical and ethical perspective. In this
report, we describe the study design, statistical considerations,
baseline characteristics of the cohort, and our experience in
implementing a large clinical trial in a resource-constrained
setting.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
Thisstudywasconducted accordingtotheprinciplesexpressedin
the Declaration of Helsinki. The study protocol and consent
documents were approved by the University of Zambia Research
Ethics Committee (reference number 002-04-06) and the University
of Alabama at Birmingham institutional review board (reference
number X060707001). Written informed consent was obtained
from all adult participants; no minors were enrolled in the study.
Study Design
‘Effectiveness of HIV Viral Load Monitoring on Patient
Outcome in Resource-Poor Settings’ - known locally as the Viral
Load Study or VLS - is a two-arm, clinic-level cluster randomized
trial to evaluate the use of routine plasma HIV-1 VL monitoring to
improve survival and decrease HIV disease progression in patients
initiating ART in Lusaka, Zambia. Participants enrolled in the
study intervention arm of VLS receive VL testing at ART
initiation and at 3, 6, 12, and 18 months post-initiation, and the
results are provided to the clinician for the purpose of patient care.
Participants in the study control arm receive ‘discretionary’ viral
load testing according to local guidelines: VL testing is performed
for those patients meeting either clinical or immunologic criteria
for treatment failure, but not both. Patients meeting both clinical
and immunologic criteria for therapeutic failure are assumed to
have virologic failure, and VL testing is not performed.
Discretionary viral load testing was performed on fewer than 7%
of all patients in the ART program in 2008. Participants in the
control arm have blood drawn according to the same schedule as
the intervention arm, but the samples are frozen and archived.
Aside from routine VL testing (in the intervention arm) or
phlebotomy (in the control arm), VLS participants receive local
standard medical care. Figure 1 describes the study design.
The primary aim of VLS is to compare mortality at 18 months
among ART-naı ¨ve patients initiating ART and receiving care at
facilities with access to routine VL testing, compared to those
initiating first regimens and receiving the current standard of care
(i.e., discretionary VL testing). The secondary objectives are (1) to
compare select indicators of clinical disease progression in the two
comparison groups (e.g., CD4+ lymphocyte response, incident
opportunistic infections, and weight loss); (2) to assess the impact of
more rapid ART regimen switching on available second and third-
line treatment options; (3) to monitor the effectiveness of newer
antiretroviral medications (principally TDF/FTC); (4) to charac-
terize the timing and sequence of HIV drug resistance develop-
ment among patients in each arm; and (5) to assess the feasibility,
acceptability, and cost effectiveness of the two management
strategies in a resource-constrained sub-Saharan African setting.
A cluster-randomized design was selected as most appropriate
from a logistical perspective to facilitate VL sample collection and
reporting of results, and from an ethical perspective to minimize
the perception among control arm participants that he/she was
receiving ‘less’ treatment. The VLS was designed as a ‘‘pragmatic’’
trial in which the intervention to be tested is overlaid on the
background of usual clinical practice, with a minimum of study-
related practice constraints, liberal inclusion, and few exclusion
criteria.
Location and Personnel
The severity and challenges of the HIV epidemic in Zambia are
typical of many sub-Saharan Africa countries. Fifteen percent of
adults (15–49 years old) are estimated to be HIV-infected [16] and
64% of the population of 11.7 million live on less than 1.25 US
dollars per day. [17] The Zambian national program for HIV care
and treatment was implemented in Lusaka’s public health sector in
April 2004 and has expanded rapidly across the country. By May
2009, 198,000 patients were enrolled in HIV care at 67 sites, and
127,000 had started ART. Clinical care in the Zambian national
ART program has been previously described. [1,18] Briefly, HIV-
infected patients undergo a history and physical examination,
WHO disease staging, and a CD4
+ lymphocyte count at enroll-
ment. Patients with WHO stage 4 disease; a CD4
+ lymphocyte
count ,200 cells/mm
3; or WHO stage 3 disease and a CD4
+
lymphocyte count ,350 mm
3 are eligible to initiate ART. We
have previously described the Zambian national guidelines for
determining clinical and immunologic treatment failure (see
also figure 1). [19] Plasma HIV-1 RNA measurements, where
available, are used sparingly to adjudicate uncertain presentations.
When VLS began enrollment in December 2006, the first-line
ART regimen was a non-nucleoside reverse transcriptase inhibitor
(NNRTI), either efavirenz (EFV) or nevirapine (NVP), in
combination with two nucleoside reverse transcriptase inhibitors
(NRTIs): lamivudine (3TC) with either zidovudine (ZDV) or
stavudine (d4T). In July 2007, the NRTI combination of tenofovir
(TDF) and emtricitabine (FTC) or 3TC was introduced as first line
therapy. Patients on treatment prior to July 2007 remained on the
original regimen, except in cases of treatment failure or toxicity.
VLS employed dedicated study staff at each clinical site to
ensure the proper follow-up of participants without detracting
from routine patient care. A clinic-based study nurse at each site
saw participants at every visit and collected serum specimens for
VL testing and archiving within a 60-day window around each
sampling point. An additional pool of four nurses provided support
or replacement staffing as needed. Each study facility also
employed a clinical assistant, who coordinated patient movement
through the clinic and ensured that study participants saw the
study nurse. Additionally, the clinical assistant worked with clinic-
based community volunteers to ensure good participant follow-up.
Recruitment and Screening
We recruited participants from 12 Lusaka district clinics. The
rationale for selection of study clinics is described below in statistical
considerations. The control and intervention arms were each
allocated six clinics. Adult patients with a documented HIV-1
infection presenting for medical care at participating clinics were
referred for screening by the VLS nurse based at each site. Study
Zambia Viral Load Trial
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study clinic at the time of screening.
Patients were eligible to enroll in the study if they qualified for
ARTperZambian nationalguidelinesand wereinitiatingtreatment
on the day of study enrollment; resided in the geographical
catchment area oftheVLSclinicandintended toremaininthearea
for the durationofstudy;agreed to adheretothestudy visitschedule
and to be followed-up at home in the event of a missed study visit;
and provided informed consent and a baseline blood draw. Patients
were ineligible if they reported receipt of more than 7 days
(cumulative) of prior ART in the past, with the exception of ZDV
prophylaxis or single dose NVP for prevention of mother-to-child
transmission (PMTCT). We also excluded those with any exposure
to ART in the prior month, those with any condition that in the
opinion of the study staff would interfere with adherence to study
requirements (e.g., mental illness or active drug use or alcohol
dependence), those who required hospital referral for a serious
illness at the time of treatment initiation; and those who refused or
were unable to provide consent to participate.
Many roads in Lusaka residential neighborhoods are unmarked,
and each participant was requested to provide a mobile phone
number (if available), and instructions or a diagram for locating
their primary residence. Contact information for a close associate
was also requested. The study nurse updates the locator form at
each visit, and clinical associates use this information to trace
participants lost to follow-up.
Data Collection
Study data are collected in the national programmatic database
and a dedicated research database. Following every patient visit, data
associates enter a range of information into the SmartCare electronic
medical record system (http://www.smartcare.org.zm) developed by
the Zambian Ministry of Health, the Centers for Disease Control and
Prevention, and the Centre for Infectious Disease Research in
Zambia.VLSparticipantinformationisalsoenteredintotheseparate
research database. A computer program routinely compares the
programmatic and research databases, and all discrepancies are
reconciled in the research database after reference to the paper chart.
VLS participant serum specimens are separated at the facility
level from programmatic specimens and transported to a central
laboratory by daily courier. HIV-1 VL is measured by the Roche
Amplicor HIV-1 RNA Monitor kit (version 1.5; Roche Molecular
Diagnostics, Pleasanton, CA, USA). CD4
+ lymphocyte counts are
performed using a Beckman Coulter flow cytometer (Beckman
Coulter, Inc., Fullerton, CA, USA); chemistry assays using an
Olympus AU400 (Olympus Diagnostics, Hamburg, Germany);
and hemogram or complete blood count with differential using a
HoribaABX Pentra80 (HoribaABX Diagnostics Inc., Montpellier,
Figure 1. Design of the Viral Load Study. * Immune Reconstitution Syndrome (IRIS) is not considered evidence of clinical treatment failure. The
assessment of whether a clinical event represents IRIS or a genuine incident opportunistic infection is determined locally by the clinician. Note: when
clinical or immunologic criteria for therapeutic failure are met, a procedure for allocating ‘discretionary’ viral load testing is utilized. Any evident
infections are investigated and treated. In cases of suspected immunologic treatment failure, the CD4
+ lymphocyte count is repeated one month
after treatment of infection and/or intensive adherence counseling. If the patient still meets criteria for therapeutic failure after adherence is judged
to be excellent and (in cases of immunologic failure) after a repeat CD4
+ lymphocyte count, HIV-1 viral load testing is performed for those patients
meeting either clinical or immunologic criteria, but not both. Patients meeting both clinical and immunologic criteria for therapeutic failure are
assumed to have virologic failure and the decision to change to ART regimen is made without viral load testing.
doi:10.1371/journal.pone.0009680.g001
Zambia Viral Load Trial
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9680France). The study maintains a specimen archive containing whole
blood from ART-initiation and plasma from each subsequent
collection point for all participants.
Statistical Considerations
Twelve ART clinics in Lusaka, Zambia constituted the units of
randomization. In order to maximize the comparability of patients
across clinics and to limit the effect of clustering within clinics (i.e.,
to lower the intraclass correlation coefficient), we stratified clinics
into pairs according to matching criteria. One clinic in each pair
was selected by a computerized randomization program to
implement VL monitoring as the standard of care (table 1). The
stratification of clinics was based primarily on estimated 18-month
mortality rates, but we also considered the duration of operation
and the number of active patients (i.e., patients with a clinic or
pharmacy visit in the preceding 90 days).
Six study clinics (Bauleni, Chawama, Chilenje, Chipata,
George, and Mtendere) were operating for over 18 months at
the time of randomization (range: 20 to 30 months as of October
1, 2006), and provided an estimated average 18-month mortality
rate of 15.6 per 100 person-years. This approximates the overall
mortality rate of 16.1 per 100 person-years previously observed in
the national ART program. [1] However, the mortality rate varied
from 13.1 per 100 person-years at George to 20.4 per 100 person-
years at Chipata, illustrating the need to account for dependence
between subjects within clinics. The calculated coefficient of
variation, k, for mortality rates at these 6 clinics was 0.14.
The six additional study clinicswere not included in the calculation
of the coefficient of variation for 18-month mortality. Matero
Reference and Kanyama clinics were selected for inclusion in the
study after the average 18-month mortality was calculated, and the
pairing was based on a similar duration of operation (26 and 30
months, respectively) and number of active patients (3,492 and 4,314,
respectively). Matero Main and Kabwata clinics were matched based
on a similarly short duration of operation (2 and 7 months,
respectively) and smaller active patient population (357 and 525,
respectively). Lastly, Makeni and Ngombe clinics were matched as
both clinics were scheduled to open after the study commenced in
December 2006.
The study was powered to detect a hazard ratio of 0.64 or lower
as a consequence of utilizing routine VL monitoring in clinical
care, which represented a 36% reduction in mortality (15.6 per
100 person-years versus 10.0 per 100 person years). Matching
clinics will permit the use of a matched k in future analyses, which
should be lower than the unmatched k and may improve study
power. Using our estimated unmatched k (0.14) as a conservative
estimate of the matched k, 1680 participants (140 per clinic; alive
or deceased) will need to remain in the study after 18 months of
follow-up to maintain the sample size assumed in the power
calculations. [20] Figure 2 shows the detectable hazard ratio (alpha
of 0.05 and beta of 0.20) at different coefficients of variation.
The primary analysis will compare mortality at 18 months between
the intervention and control arms, while taking into account the
design-based cluster matching and the testing of the intervention effect
over all community pairs. The difference in mortality for each
matched pair will be computed and statistical significance will be
assessed using a paired t-test or the non-parametric rank sum test.
While matching on clinic character i s t i c si se x p e c t e dt op r o d u c e
balance with respect to clinic related factors, imbalances in other
covariates (e.g., socio-economic status, age distribution) will be adjusted
at the cluster level using an extension of the Mantel-Haenzsel test.
We calculated an enrollment target of 2100, or 175 participants
per clinic, by assuming an attrition rate (voluntary withdrawals
and loss to follow-up) of 20% at 18 months based on historical
estimates. We expected to have at least 1680 participants (alive or
deceased) remaining in the study cohort at completion.
Patients who move from one study clinic catchment area to
another study clinic area are continued in their original assigned
study arm, regardless of the assignment of the second clinic. Patients
who move to areas served by non-study clinics are encouraged to
continue attending the study clinic, but are classified as withdrawn if
they do not.
Brief treatment interruptions are not uncommon among ART
patients in Lusaka, often due to familial or economic factors.
Patients in the national ART program, and VLS participants, are
classified as lost to follow-up when (1) .37 days late for a scheduled
pharmacy visit, or (2) do not to return within 60 days of the last
clinical visit if no pharmacy visit was scheduled. However,
Table 1. Matched study clinic pairs (As of December 1, 2006, prior to study commencement).
Study clinic Study arm
Duration of operation
(months)
Number of adult patients
on ART*
Probability of survival at 18 months
(95%CI)
{
Matero Ref. Intervention 28.0 2,375 0.86 (0.85, 0.88)
Kanyama Control 31.1 2,728 0.88 (0.86, 0.89)
Chipata Intervention 21.9 1,151 0.82 (0.80, 0.85)
Chawama Control 9.0 775 0.92 (0.90, 0.95)
George Intervention 28.0 1,460 0.87 (0.85, 0.89)
Chilenje Control 27.0 1,097 0.85 (0.83, 0.87)
Mtendere Intervention 31.1 1,044 0.85 (0.83, 0.87)
Bauleni Control 23.4 456 0.82 (0.78, 0.86)
Kabwata Intervention 8.5 297 0.95 (0.90, 0.99)
Matero Main Control 4.0 227 0.91 (0.85, 0.96)
Ngombe
{ Intervention 0 0 na
Makeni
{ Control 0 0 na
*Excludes former patients classified as deceased or lost to follow-up.
{Kaplan-Meier estimate of the proportion of adult patients surviving at 18 months post-ART initiation.
{Ngombe and Makeni clinics opened in March 2007.
doi:10.1371/journal.pone.0009680.t001
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the study if they return to care within 120 days.
Results
Between December 2006 and May 2008, we enrolled 1973
participants at 12 clinics (figure 3). This represents 47% of
the 4,215 patients screened and 26% of the 7,723 patients
initiating ART at participating study sites. Enrollment was
staggered by clinic pairs to permit close staff support (Figure 4).
Ten of the 12 sites were fully enrolled. Enrollment at Ngombe
and Makeni was halted after 111 and 115 participants,
respectively, owing to lower than anticipated patient volumes at
each site.
Figure 2. Detectable hazard ratio as a consequence of utilizing routine HIV-1 viral load monitoring at varying between-clinic
coefficients of variation. Calculation assumes a historical 18 month post-ART mortality rate of 15.6 per 100 years (140 patients remaining per clinic).
doi:10.1371/journal.pone.0009680.g002
Figure 3. Participant screening and enrollment.
doi:10.1371/journal.pone.0009680.g003
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shown in Table 2. Overall, the mean age was 34.6, 61% were
female, 78% had a CD4
+ lymphocyte count ,200 cells/mm
3,
14% had a CD4
+ lymphocyte count ,50 cell/mm
3, and 68% had
WHO stage 3 or 4 disease at enrollment. The first-line ART
regiments included NVP (74%) or EFV (25%), and ZDV (40%),
d4t (36%) or TDF (24%). There were no significant differences in
measured baseline characteristics between study arms (p,0.05).
Discussion
The implementation of a large clinical trial of HIV-1 VL
monitoring in the context of a dynamic, rapidly growing national
ART program is challenging but feasible. Our experience can
inform investigators working in similar settings. The VLS will
provide a range of critical data on the role of virologic monitoring
of patients on ART in resource-constrained settings, and the
specimen archive offers a unique opportunity to investigate a host
of future research questions. Randomized controlled trials such as
the VLS will likely prove valuable in determining long-term
outcomes in resource-constrained settings.
This study represents a successful collaboration between the
study team and the national ART program during a period of
rapid expansion. Investigators and trial administrators need the
resources and reserve capacity to adjust staffing levels in response
to deficiencies, and must avoid diverting personnel from the
national program while also delineating study staff responsibilities
in an environment of competing needs. In selecting study staff,
candidates with experience in government ART clinics are
preferred, but senior management must closely monitor all staff
initially to address deficiencies and ensure the collection of study
data and specimens within the specified time period. Close
communication between investigators and district health manag-
ers, and attention to disagreements between study staff and
ART clinic staff, are essential to promote prompt resolution and
improve study integration. Early provision of informational
materials and/or presentations to non-study clinic staff may
increase the general perception that the study is relevant and an
appropriate use of resources.
Our clinic-level, cluster randomization design accounted for the
lack of independence of subjects within clinic populations.
Matching clinics according to facility-level characteristics yielded
a study cohort without significant differences in baseline
participant characteristics in each arm. However, our method
may have missed important differences in the patient populations
served by each clinic (e.g., socio-economic status), and insufficient
randomization may result in the emergence of confounding
variables as the study progresses. Additionally, the baseline
characteristics of participants remaining in each arm at study
conclusion will need to be compared to determine potential
selection effects of the intervention versus study participation
alone. A coefficient of variation for overall 18-month mortality
rate among study clinics, and a matched k, will be calculated at
study conclusion to determine the final detectable hazard ratio.
Under-enrollment in one clinic-pair (Ngombe and Makeni)
reduced our sample size to 1973 participants from a target of
2100. Our statistical power calculations assumed an 18-month
attrition rate of 20% based on historical data, which would yield a
final cohort of 1578 participants (132 per clinic), as opposed to
1680 (140 per clinic), after 18 months of follow-up. This reduction
in the size of the analysis cohort, if present, will have a minimal
effect on our statistical power due to the cluster randomized
Figure 4. Participant accrual by clinic. Superscript denotes matched clinic pairs. ‘Matero Ref.’ refers to Matero Reference clinic.
doi:10.1371/journal.pone.0009680.g004
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variation between clinics exerts a greater impact on statistical
calculations than the number of participants per clinic. Assuming
132 participants per clinic remain at 18 months and the estimated
coefficient of variation of 0.14 does not change, we would still be
able to detect a hazard ratio of 0.637 or lower, as opposed to 0.642
or lower, as a consequence of utilizing routine VL monitoring in
clinical care.
Losses to follow-up are an important source of bias in
prospective studies, and lost participants may differ from those
continuing follow-up. We estimated an 18-month attrition rate
of 20% from historical data, but estimates of mortality and
attrition rates should account for potential changing norms among
future patient populations and the effect of study participation.
We attempted to minimize bias from ‘contamination’ effects –
for example, if participants from control clinics switched to
intervention clinics to take advantage of additional clinical
services. Given that control arm patients are aware of, but do
not receive, additional clinical services, there may be increased loss
in this arm.
The investigators recently decided to extend the follow-up
period of participants in the VLS to 36 months to accrue
additional data on mortality, virologic failure, and other outcomes
in this unique cohort. This extension will better inform a range of
secondary research questions, including differences in immuno-
logic response and clinical disease progression between study arms;
the impact of more frequent ART regimen switching in the setting
of limited available third-line and beyond treatment regimens; the
incidence and pattern of accumulated HIV resistance mutations;
and the cost-effectiveness of the two management strategies.
Participant retention will be critical to maximizing study yield over
this longer period, while a divergence in study clinic mortality
rates, with a corresponding increase in the coefficient of variation,
could adversely affect statistical power. The investigators intend to
disseminate the study findings at the completion of the 36 month
trial, rather than reporting interim 18 month findings, to avoid a
potential effect on clinician behavior or the validity of the final
results.
Overall, VLS has responded well to unforeseen circumstances,
but additional resources will need to be committed to extend
participant follow-up. Close collaboration and frequent reporting
between investigators, senior research staff, and clinic-based staff is
a necessity to ensure scheduled data and specimen collection,
especially given the constraints of local clinical, laboratory, and
transport infrastructure, and the difficulties of locating participants
in the community. The VLS cohort will provide a range of
important data on the monitoring and long-term outcomes of
patients on ART in resource constrained settings.
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Table 2. Baseline characteristics of participants by study arm.
Control Arm
(N=984)
Intervention Arm
(N=989)
N Value N Value
Age, mean years (sd) 984 34.3 (8.4) 989 34.8 (8.3)
Sex
Female 600 61.0% 584 59.0%
Male 384 39.0% 405 41.0%
Viral Load, mean log10 copies/mL
(sd)
988 5.1 (0.8)
#100,000 copies/mL NA 358 36.2%
.100,000 copies/mL NA 630 63.8%
Adherence Support
No 13 1.3% 25 2.5%
Yes 971 98.7% 964 97.5%
CD4
+ Lymphocyte Count, mean
cells/mm
3 (sd)
957 146 (82.6) 941 145 (86.8)
$200 cells/mm
3 194 20.3% 223 23.7%
50–199 cells/mm
3 652 68.1% 572 60.8%
,50 cells/mm
3 111 11.6% 146 15.5%
WHO Stage
I or II 308 32.8% 295 31.1%
III 561 59.7% 560 59.1%
IV 70 7.5% 93 9.8%
Hemoglobin, mean g/dL (sd) 952 10.9 (2.1) 944 11.0 (2.1)
$8.0 g/dL 878 92.2% 879 93.1%
,8.0 g/dL 74 7.8% 65 6.9%
Body Mass Index, mean kg/m
2 (sd) 962 20.4 (3.4) 960 20.3 (3.7)
$16 kg/m
2 894 92.9% 884 92.1%
,16 kg/m
2 68 7.1% 76 7.9%
Creatinine Clearance, mean mL/min
(sd)*
894 59.7 (26.4) 929 59.7 (22.4)
Normal 703 78.8% 713 76.9%
Abnormal 189 21.2% 214 23.1%
Alanine Aminotransferase, mean
u/L (sd)**
902 22.4 (18.0) 936 23.1 (16.2)
Normal 869 96.3% 899 96.0%
Abnormal 33 3.7% 37 4.0%
Anti-Tuberculosis Therapy
No 807 82.0% 833 84.2%
Yes 177 18.0% 156 15.8%
Antiretroviral Regimen
ZDV + 3TC + NVP 345 35.2% 359 36.3%
ZDV + 3TC + EFV 44 4.5% 46 4.7%
D4T + 3TC + NVP 275 28.1% 314 31.8%
D4T + 3TC + EFV 65 6.6% 52 5.3%
TDF + FTC + NVP 114 11.6% 57 5.8%
TDF + FTC + EFV 134 13.7% 157 15.9%
Other 2 0.2% 3 0.3%
Note: missing baseline values and values not collected within the required time
period are not shown.
*Normal creatinine clearance (calculated using the Cockcroft-Gault equation)
$90 mL/min.
**Normal alanine aminotransferase ,62.5 u/L.
doi:10.1371/journal.pone.0009680.t002
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